Jiangsu Hengrui, Incyte deal

Jiangsu Hengrui granted Incyte exclusive rights to develop and commercialize SHR-1210 outside of Taiwan and China. The mAb against PD-1 is in an Australian Phase I trial to treat patients with advan...